Opendata, web and dolomites

BERMES SIGNED

A Novel BERberine derivative for Malignant MESothelioma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BERMES project word cloud

Explore the words cloud of the BERMES project. It provides you a very rough idea of what is the project "BERMES" about.

oral    exposure    survival    world    clinical    peritoneal    tissue    2020    right    authorization    first    emergence    burden    aggressive    drug    pemetrexed    diagnosis    none    thin    heart    latency    translational    data    health    manufacture    solved    mesothelioma    incidences    administered    banned    testis    trials    pulling    completion    cavity    undertaken    last    44    toxicity    despite    therapy    period    antitumour    combination    gap    2005    lungs    line    preliminary    regulatory    worldwide    berberine    mm    orphan    malignancy    close    nax035    agent    improvement    deal    valley    definitely    innovative    efficacy    bermes    medicine    january    good    agency    malignant    derivative    union    layer    covers    designation    safety    exhibited    cisplatin    peak    obtaining    mesothelium    drugs    asbestos    death    organs    limited    chemoresistance    forms    pharmacokinetic    treatment    arising    rare    internal    disease    organization    trial    resistant    shown    standard   

Project "BERMES" data sheet

The following table provides information about the project.

Coordinator
APPLIED RESEARCH USING OMIC SCIENCES SL 

Organization address
address: CALLE VICTOR PRADERA 45
city: CORNELLA
postcode: 8940
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 1˙550˙942 €
 EC max contribution 1˙085˙659 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    APPLIED RESEARCH USING OMIC SCIENCES SL ES (CORNELLA) coordinator 1˙085˙659.00

Map

 Project objective

Malignant Mesothelioma (MM) is a rare, aggressive and highly treatment-resistant malignancy arising in the thin layer of tissue known as mesothelium, which covers many of the important internal organs like the lungs, the peritoneal cavity, the heart and the testis. The World Health Organization has recognized that all forms of mesothelioma are strongly associated with asbestos exposure and that its burden is increasing worldwide. Asbestos was definitely banned in European Union in January 2005. However, since the disease has a long latency period (44.6 years from exposure to diagnosis), peak incidences are expected in EU beyond 2020. The standard first line treatment is the combination of pemetrexed and cisplatin with limited efficacy and side-effects. Despite a great deal of research has been undertaken during the last 10 years, none of the current drugs under clinical trials has shown yet an improvement in overall survival over existing standard therapy or solved the emergence of chemoresistance. NAX035, an innovative berberine derivative has exhibited efficacy as antitumour agent with a good preliminary pharmacokinetic, toxicity and safety data when administered as oral therapy for the treatment of malignant mesothelioma. Activities of BERMES (BERberine derivative for MESothelioma treatment are expected to close the translational gap (death valley) by pulling the product up to the clinical development: BERMES will focus on completion of the non-clinical package and the drug manufacture with the aim of obtaining the orphan drug designation as well as to accomplish all the regulatory requirements required by the European Medicine Agency to achieve the clinical trial authorization to proceed into clinical trial right after the end of the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BERMES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BERMES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More